The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection

Guy W. Neff, J. Delagarza, N. Shire, Seigo Nishida, Christopher B O'Brien, K. Safdar, J. Madariaga, Eugene R Schiff, Phillip Ruiz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction. Adequate immune suppression following liver transplantation in recipients with recurrence of hepatitis C virus (HCV) is not standardized. The aim of this study was to evaluate the association between immune suppression protocol and the clinical/histological parameters in HCV transplant recipients with an HCV recurrence. Methods. A retrospective analysis was performed on recipients of liver transplants from June 1998 to October 2003 who experienced HCV recurrence. Only patients with liver biopsies at 3 to 5 years following liver transplantation were included in the analysis. The data set included: patient demographics, immune suppression, antiviral therapies, as well as histology to evaluate ductopenia and chronic rejection. Patients divided into groups of high, medium, and low immune suppression were subdivided by treatment with versus without interferon. A control group with similar demographics suffering from cryptogenic cirrhosis was used for comparison. Results. During this period 45 patients had liver biopsies at 3 to 5 years posttransplantation. Their mean age was 56.5 years and mean time from transplant to biopsy was 1543 days. Their average posttransplant survival was 1964 days. There was no difference among the three groups with respect to HCV RNA levels (log 10 IU/mL), age, gender, time from transplant, donor age, and UNOS status. Median HCV RNA levels within the three groups were comparable at various time periods pre- and posttransplant. Conclusion. The development of chronic allograft damage following transplantation in recipients with recurrent HCV tended to be worse among patients with low levels of immune suppression, suggesting the importance of therapy to maintain allograft function.

Original languageEnglish
Pages (from-to)3065-3067
Number of pages3
JournalTransplantation Proceedings
Volume36
Issue number10
DOIs
StatePublished - Dec 1 2004

Fingerprint

Virus Diseases
Hepatitis C
Hepacivirus
Liver
Biopsy
Recurrence
Liver Transplantation
Allografts
Demography
RNA
Clinical Protocols
Transplant Recipients
Interferons
Antiviral Agents
Histology
Therapeutics
Transplantation
Tissue Donors
Transplants
Control Groups

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection. / Neff, Guy W.; Delagarza, J.; Shire, N.; Nishida, Seigo; O'Brien, Christopher B; Safdar, K.; Madariaga, J.; Schiff, Eugene R; Ruiz, Phillip.

In: Transplantation Proceedings, Vol. 36, No. 10, 01.12.2004, p. 3065-3067.

Research output: Contribution to journalArticle

Neff, Guy W. ; Delagarza, J. ; Shire, N. ; Nishida, Seigo ; O'Brien, Christopher B ; Safdar, K. ; Madariaga, J. ; Schiff, Eugene R ; Ruiz, Phillip. / The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 10. pp. 3065-3067.
@article{c716a18aaf9d4a4ab4ac255adf3751e2,
title = "The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection",
abstract = "Introduction. Adequate immune suppression following liver transplantation in recipients with recurrence of hepatitis C virus (HCV) is not standardized. The aim of this study was to evaluate the association between immune suppression protocol and the clinical/histological parameters in HCV transplant recipients with an HCV recurrence. Methods. A retrospective analysis was performed on recipients of liver transplants from June 1998 to October 2003 who experienced HCV recurrence. Only patients with liver biopsies at 3 to 5 years following liver transplantation were included in the analysis. The data set included: patient demographics, immune suppression, antiviral therapies, as well as histology to evaluate ductopenia and chronic rejection. Patients divided into groups of high, medium, and low immune suppression were subdivided by treatment with versus without interferon. A control group with similar demographics suffering from cryptogenic cirrhosis was used for comparison. Results. During this period 45 patients had liver biopsies at 3 to 5 years posttransplantation. Their mean age was 56.5 years and mean time from transplant to biopsy was 1543 days. Their average posttransplant survival was 1964 days. There was no difference among the three groups with respect to HCV RNA levels (log 10 IU/mL), age, gender, time from transplant, donor age, and UNOS status. Median HCV RNA levels within the three groups were comparable at various time periods pre- and posttransplant. Conclusion. The development of chronic allograft damage following transplantation in recipients with recurrent HCV tended to be worse among patients with low levels of immune suppression, suggesting the importance of therapy to maintain allograft function.",
author = "Neff, {Guy W.} and J. Delagarza and N. Shire and Seigo Nishida and O'Brien, {Christopher B} and K. Safdar and J. Madariaga and Schiff, {Eugene R} and Phillip Ruiz",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2004.11.005",
language = "English",
volume = "36",
pages = "3065--3067",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection

AU - Neff, Guy W.

AU - Delagarza, J.

AU - Shire, N.

AU - Nishida, Seigo

AU - O'Brien, Christopher B

AU - Safdar, K.

AU - Madariaga, J.

AU - Schiff, Eugene R

AU - Ruiz, Phillip

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Introduction. Adequate immune suppression following liver transplantation in recipients with recurrence of hepatitis C virus (HCV) is not standardized. The aim of this study was to evaluate the association between immune suppression protocol and the clinical/histological parameters in HCV transplant recipients with an HCV recurrence. Methods. A retrospective analysis was performed on recipients of liver transplants from June 1998 to October 2003 who experienced HCV recurrence. Only patients with liver biopsies at 3 to 5 years following liver transplantation were included in the analysis. The data set included: patient demographics, immune suppression, antiviral therapies, as well as histology to evaluate ductopenia and chronic rejection. Patients divided into groups of high, medium, and low immune suppression were subdivided by treatment with versus without interferon. A control group with similar demographics suffering from cryptogenic cirrhosis was used for comparison. Results. During this period 45 patients had liver biopsies at 3 to 5 years posttransplantation. Their mean age was 56.5 years and mean time from transplant to biopsy was 1543 days. Their average posttransplant survival was 1964 days. There was no difference among the three groups with respect to HCV RNA levels (log 10 IU/mL), age, gender, time from transplant, donor age, and UNOS status. Median HCV RNA levels within the three groups were comparable at various time periods pre- and posttransplant. Conclusion. The development of chronic allograft damage following transplantation in recipients with recurrent HCV tended to be worse among patients with low levels of immune suppression, suggesting the importance of therapy to maintain allograft function.

AB - Introduction. Adequate immune suppression following liver transplantation in recipients with recurrence of hepatitis C virus (HCV) is not standardized. The aim of this study was to evaluate the association between immune suppression protocol and the clinical/histological parameters in HCV transplant recipients with an HCV recurrence. Methods. A retrospective analysis was performed on recipients of liver transplants from June 1998 to October 2003 who experienced HCV recurrence. Only patients with liver biopsies at 3 to 5 years following liver transplantation were included in the analysis. The data set included: patient demographics, immune suppression, antiviral therapies, as well as histology to evaluate ductopenia and chronic rejection. Patients divided into groups of high, medium, and low immune suppression were subdivided by treatment with versus without interferon. A control group with similar demographics suffering from cryptogenic cirrhosis was used for comparison. Results. During this period 45 patients had liver biopsies at 3 to 5 years posttransplantation. Their mean age was 56.5 years and mean time from transplant to biopsy was 1543 days. Their average posttransplant survival was 1964 days. There was no difference among the three groups with respect to HCV RNA levels (log 10 IU/mL), age, gender, time from transplant, donor age, and UNOS status. Median HCV RNA levels within the three groups were comparable at various time periods pre- and posttransplant. Conclusion. The development of chronic allograft damage following transplantation in recipients with recurrent HCV tended to be worse among patients with low levels of immune suppression, suggesting the importance of therapy to maintain allograft function.

UR - http://www.scopus.com/inward/record.url?scp=21244447674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244447674&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.11.005

DO - 10.1016/j.transproceed.2004.11.005

M3 - Article

C2 - 15686695

AN - SCOPUS:21244447674

VL - 36

SP - 3065

EP - 3067

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -